{"id":"https://openalex.org/W4361908390","doi":"https://doi.org/10.1158/1078-0432.22450787","title":"Supplementary Figure 2 from \u03b3-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)","display_name":"Supplementary Figure 2 from \u03b3-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361908390","doi":"https://doi.org/10.1158/1078-0432.22450787"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22450787","doi":"https://doi.org/10.1158/1078-0432.22450787","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22450787","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.22450787","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103434536","display_name":"Jenny Wu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jenny Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108677744","display_name":"Peter H. Clingen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter H. Clingen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040495838","display_name":"Victoria J. Spanswick","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Victoria J. Spanswick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086908702","display_name":"Maria Mellinas\u2010Gomez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Mellinas-Gomez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060350068","display_name":"Tim Meyer","orcid":"https://orcid.org/0000-0003-0782-8647","observed_orcids":["https://orcid.org/0000-0003-0782-8647","https://orcid.org/0000-0003-2994-9693"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tim Meyer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Igor Puzanov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071360446","display_name":"Duncan Ian Jodrell","orcid":"https://orcid.org/0000-0001-9360-1670","observed_orcids":["https://orcid.org/0000-0001-9360-1670"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Duncan Jodrell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085123244","display_name":"Daniel Hochhauser","orcid":"https://orcid.org/0000-0001-5522-9281","observed_orcids":["https://orcid.org/0000-0001-5522-9281"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Hochhauser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5055669649","display_name":"John Anthony Hartley","orcid":"https://orcid.org/0000-0003-3737-9897","observed_orcids":["https://orcid.org/0000-0003-3737-9897"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John A. Hartley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10433","display_name":"Carcinogens and Genotoxicity Assessment","score":0.3244999945163727,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10433","display_name":"Carcinogens and Genotoxicity Assessment","score":0.3244999945163727,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.3075999915599823,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.10610000044107437,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gamma-h2ax-foci","display_name":"\u03b3H2AX foci","score":0.9639999866485596},{"id":"https://openalex.org/keywords/dna-damage","display_name":"DNA damage","score":0.7360000014305115},{"id":"https://openalex.org/keywords/dna-cross-linking-agents","display_name":"DNA cross-linking agents","score":0.8960000276565552},{"id":"https://openalex.org/keywords/sjg-136","display_name":"SJG-136","score":0.9419999718666077},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.9100000262260437},{"id":"https://openalex.org/keywords/human-lymphocytes","display_name":"human lymphocytes","score":0.871999979019165},{"id":"https://openalex.org/keywords/inter-assay-variation","display_name":"inter-assay variation","score":0.7889999747276306},{"id":"https://openalex.org/keywords/intra-assay-variation","display_name":"intra-assay variation","score":0.9860000014305115}],"concepts":[{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.531825840473175},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5225324630737305},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.49910593032836914},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.4978604316711426},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.43241703510284424},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4273075759410858},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30440986156463623},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.2921493947505951},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.23179760575294495},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.2204056680202484},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1370590627193451},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.11357331275939941}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22450787","doi":"https://doi.org/10.1158/1078-0432.22450787","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22450787","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22450787.v1","doi":"https://doi.org/10.1158/1078-0432.22450787.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450787.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_2_from_-H2AX_Foci_Formation_as_a_Pharmacodynamic_Marker_of_DNA_Damage_Produced_by_DNA_Cross-Linking_Agents_Results_from_2_Phase_I_Clinical_Trials_of_SJG-136_SG2000_/22450787/1/files/39901865.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22450787","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_2_from_-H2AX_Foci_Formation_as_a_Pharmacodynamic_Marker_of_DNA_Damage_Produced_by_DNA_Cross-Linking_Agents_Results_from_2_Phase_I_Clinical_Trials_of_SJG-136_SG2000_/22450787","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22450787","doi":"https://doi.org/10.1158/1078-0432.22450787","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22450787","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.6240000128746033,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361908390.pdf","grobid_xml":"https://content.openalex.org/works/W4361908390.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7028850227","https://openalex.org/W4361944298","https://openalex.org/W2008638513","https://openalex.org/W1564587970","https://openalex.org/W7033254127","https://openalex.org/W4416746497","https://openalex.org/W7053131035","https://openalex.org/W2023737262","https://openalex.org/W7005935493","https://openalex.org/W2317322292"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2,17,29],"59K,":[3],"Validation":[4],"experiments":[5],"in":[6],"human":[7],"lymphocytes":[8],"treated":[9],"ex":[10],"vivo":[11],"with":[12,56],"SJG-136.":[13],"A.":[14],"Inter-assay":[15],"variation":[16,28],"mean":[18,30,65],"\ufffd":[19,31,66],"s.e.":[20,32,67],"data":[21,33],"from":[22,34,68],"three":[23,40],"independent":[24,41],"experiments.":[25],"B.":[26],"Intra-assay":[27],"the":[35,46,64],"same":[36,47],"samples":[37,50],"assayed":[38,55],"on":[39],"occasions.":[42],"C.":[43],"Aliquots":[44],"of":[45,59,76],"internal":[48,70],"standard":[49,71],"stored":[51],"at":[52],"-80oC":[53],"were":[54],"each":[57],"set":[58],"clinical":[60],"samples.":[61],"Data":[62],"are":[63],"10":[69],"runs":[72],"over":[73],"a":[74],"period":[75],"several":[77],"months.":[78]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}